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Background: This study aimed to evaluate the efficacy of mesenchymal stem cell (MSC) transplantation to mitigate
abnormalities in cardiac-specific and systemic metabolism mediated by a combination of a myocardial infarction
and diet-induced insulin resistance.
Methods: C57BL/6 mice were high-fat fed for eight weeks prior to induction of a myocardial infarction via chronic
ligation of the left anterior descending coronary artery. MSCs were administered directly after myocardial infarction
induction through a single intramyocardial injection. Echocardiography was performed prior to the myocardial
infarction as well as seven and 28 days post-myocardial infarction. Hyperinsulinemic-euglycemic clamps coupled
with 2-[14C]deoxyglucose were employed 36 days post-myocardial infarction (13 weeks of high-fat feeding) to
assess systemic insulin sensitivity and insulin-mediated, tissue-specific glucose uptake in the conscious, unrestrained
mouse. High-resolution respirometry was utilized to evaluate cardiac mitochondrial function in saponin-
permeabilized cardiac fibers.
Results: MSC administration minimized the decline in ejection fraction following the myocardial infarction. The
greater systolic function in MSC-treated mice was associated with increased in vivo cardiac glucose uptake and
enhanced mitochondrial oxidative phosphorylation efficiency. MSC therapy promoted reductions in fasting arterial
glucose and fatty acid concentrations. Additionally, glucose uptake in peripheral tissues including skeletal muscle
and adipose tissue was elevated in MSC-treated mice. Enhanced glucose uptake in these tissues was associated
with improved insulin signalling as assessed by Akt phosphorylation and prevention of a decline in GLUT4 often
associated with high-fat feeding.
Conclusions: These studies provide insight into the utility of MSC transplantation as a metabolic therapy that
extends beyond the heart exerting beneficial systemic effects on insulin action.
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The regional loss of cardiac myocytes following a myocar-
dial infarction (MI) compromises the ability of the heart
to pump blood to peripheral sites and may initiate com-
pensatory mechanisms in an attempt to preserve cardiac
function [1]. Researchers in regenerative medicine have* Correspondence: cchughey@ucalgary.ca
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reproduction in any medium, provided the orbecome excited by the possibility of repairing and/or re-
placing pathological tissue via administration of exogen-
ous cells [2-4]. Experimental study and clinical trials have
identified cell-based therapies to consistently improve sys-
tolic function [5-10]. However, cell transplantation has
been less than adequate at replacing the lost cells; which
may be, in part, due to poor cell persistence following ad-
ministration in the infarcted heart [11,12].
In the presence of poor cell survival and engraftment,
the mechanisms promoting beneficial results reported
following stem cell transplantation have been subject tol Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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paracrine effects are likely the major mediator for the im-
provement in cardiac function and the attenuation or
slowing of the maladaptive processes [10]. The release of
paracrine factors have a potential regulatory role in various
processes that influence cardiac function including anti-
apoptotic signalling and neovascularization as well as the
modulation of inflammation, fibrosis, cardiac contractility,
host stem cell activation and metabolism [10,13].
In terms of cardiac metabolism, animal studies indi-
cate the ability of stem cell transplantation, specifically
mesenchymal stem cell (MSC) transplantation, to lessen
aberrations in glucose utilization, mitochondrial function
and high-energy phosphate provision in the infarcted
heart [14-18]. Since diabetes and heart disease often
co-aggregate [19-21], the absence of metabolic dys-
function associated with type 2 diabetes in previous
studies may not provide a complete model in assessing
the utility of cell transplantation for the infarcted
heart. Of particular interest is insulin resistance, as it
enhances the risk of experiencing cardiovascular dis-
ease and a MI [22,23]. Moreover, individuals with insu-
lin resistance and type 2 diabetes exhibit a greater
probability of developing heart failure and higher mor-
tality following a MI [22,24,25].
From a mechanistic perspective, insulin resistance may
enhance cardiac pathology following a MI by inhibiting
changes in metabolic characteristics that are initially
suggested to be adaptive [26-30]. The cardiac metabolic
phenotype shifts away from its predominant reliance on
fatty acid oxidation towards increased glucose utilization
early post-MI [26-30]. Glucose oxidation is more oxygen
efficient and may provide a more effective means of ATP
provision [31]. An alternative means of providing energy
for cardiac contraction in an economical fashion in-
volves the down-regulation of mitochondrial uncoupling
proteins (UCPs) in the failing heart [31,32]. UCPs create
an environment where oxygen consumption does not
contribute to ATP synthesis, which is achieved through
the uncoupling of the electrochemical gradient and ADP
phosphorylation [33]. These adaptations in cardiac meta-
bolic pathways may assist in meeting the energetic de-
mand of contraction. However, this metabolic flexibility
demonstrated by the heart is impeded in insulin resist-
ance [34]. Insulin resistance inhibits glucose uptake cre-
ating a situation of severe detriment given both fatty
acid and glucose metabolism are impaired and energy
provision is compromised in the insulin resistant, in-
farcted heart [34]. Further insult occurs from hypergly-
cemia and hyperlipidemia [35,36]. For example, elevated
circulating fatty acids promote an increase in cardiac
UCP3 levels [37]. The increase in UCP3 may stimulate
higher mitochondrial uncoupling and further energy de-
mand/supply disparities.Given the deleterious impact of insulin resistance on the
infarcted heart, this study aimed to identify whether the
efficacy of MSC administration to minimize alterations in
metabolic processes that assist in ATP provision following
a MI is maintained in a murine model of diet-induced in-
sulin resistance/MI.
Methods
See Figure 1 for a schematic of experimental outline.
Animal characteristics and myocardial infarction
Procedures were approved by the Vanderbilt University
Animal Care and Use Committee and performed according
to the Guide for the Care and Use of Laboratory Animals
published by the National Institutes of Health (NIH Publi-
cation No. 85–23, revised 1996, A3227-01). Thirteen week-
old, eight week high-fat fed (HFF) (F3282, 60% calories
from fat, Bio-Serv, Frenchtown, NJ, USA), C57BL/6J,
male mice (Jackson Laboratories, Bar Harbour, ME,
USA) were randomly separated into three groups: SHAM,
MI + phosphate buffered saline (MI + PBS) and MI +
mesenchymal stem cells (MI +MSC). A left anterior
descending coronary artery (LAD) chronic ligation in-
duced a MI as described [18]. Following the ligation,
25 μl of PBS (pH 7.2) or 2.5 × 105 MSCs in 25 μl of
PBS (pH 7.2) were injected into the blanching peri-
infarct area of the MI + PBS or MI +MSC mice,
respectively.
Mesenchymal stem cells
MSCs reputedly display immunoprivileged characteris-
tics that make the use of this cell type attractive for cell
transplantation purposes [38-40]. These unique charac-
teristics provide promise for use of MSCs in not only au-
tologous transplantation but allogenic and xenogenic
transplantation. Given this, human MSCs were pur-
chased from the Texas A&M Health Science Center Col-
lege of Medicine Institute for Regenerative (Temple, TX,
USA) that provides standardized MSC preparations
through support from the NIH/NCRR (P40 RR 17447–06).
The MSCs have been described to consistently exhibit
trilineage potential and be CD90+, CD105+, CD49c+,
CD49f+, CD166+, CD105+, CD29+, CD44+, CD45-, CD34-,
CD117- and CD36- [41]. MSCs were expanded in alpha
minimum essential medium (αMEM) with L-glutamine
(Life Technologies, Burlington, ON, Canada), 16.5% de-
fined FBS (HyClone, Logan, UT, USA), penicillin (100
units/ml) and streptomycin (100 μg/ml). All mice received
MSCs from a single donor and passages 3–8 were utilized.
Cardiac performance
To assess cardiac contractile function, M-mode echo-
cardiography was completed in conscious mice at
8 week high-fat fed (HFF) (Day 0)  
Echocardiography  (Day 0, Day 7, Day 28) 
Day 0: Surgery #1 (Thoracotomy, LAD ligation, MSC 
injection) 
Day 28: Surgery #2 (Jugular vein and carotid artery 
catheterization)  
Body composition (Day 28) 
2-[14C]DG 
Insulin infusion (4mU/ kg/ min) 
Variable glucose infusion   
Euglycemia (~7.0 mM)                                        
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Figure 1 Schematic representation of experimental procedures and timeline. Echocardiography on conscious mice was performed prior to,
seven and 28 days following ligation of the left anterior descending coronary artery (LAD). Arterial and jugular catheterization was performed
28 days following the LAD ligation for the sampling and infusion protocols of the hyperinsulinemic-euglycemic (insulin) clamp. Insulin clamps
were performed following seven days of recovery from the catheterization surgeries (36 days post-LAD ligation/13 weeks of high-fat feeding) to
assess insulin action in the conscious, unrestrained mouse. Isotopic tracer 2-[14C]deoxyglucose (2-[14C]DG) administration during the insulin
clamps allowed for whole body and tissue-specific substrate uptake to be assessed in vivo. Additional experiments included evaluation of
mitochondrial respiration in permeabilized cardiac tissue and key molecular regulators of metabolism by immunoblotting. MI + PBS, myocardial
infarction + phospho-buffered saline; MI + MSC, myocardial infarction +mesenchymal stem cells.
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scribed [42,43].
Catheterization procedures
Chronic catheterization surgeries were performed 28 days
post-ligation (12 weeks HFF) as those previously described
for hyperinsulinemic-euglycemic (insulin clamps) [18].
Post-surgery, the mice were housed individually for seven
days to ensure the mice were within 10% of pre-surgical
weight prior to insulin clamps.
Hyperinsulinemic-euglycemic clamps
Our laboratory has shown that insulin resistance is induced
in 12 weeks HFF C57BL/6 mice [44,45]. Insulin clamps
were performed with procedural considerations previously
described [46] at 36 days post-MI (13 weeks HFF). Mice
were fasted at 7:00 a.m., five hours prior to initiation of the
insulin clamps. One hour prior to the experiment, theexternalized mouse catheters were connected to catheter
extensions attached to infusion syringes. Just prior to the
onset of the insulin clamp, an arterial blood sample was
obtained to evaluate levels of arterial glucose, insulin, non-
esterified fatty acids (NEFA) and hematocrit. Each experi-
ment consisted of a continuous infusion (4 mU/kg/min) of
insulin. Euglycemia (~7.0 mM) was maintained during
the insulin clamps. Venous infusion of saline-washed
erythrocytes (5 μl/min) during the insulin clamp
prevented a decline in hematocrit due to arterial sampling.
Insulin clamp duration averaged 122.07 ± 9.48 minutes
until a stable glucose infusion rate (GIR) and euglycemia
was achieved for at least 30 minutes. Arterial blood was
sampled to determine glucose levels (t = 0 minutes) had
achieved the steady state. Immediately following the blood
sampling, a bolus containing 2-[14C]deoxyglucose (2-[14C]
DG; 481 kBq) was administered into the jugular vein to
provide an index of tissue-specific glucose uptake. At
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to determine glucose and 2-[14C]DG. At t = 30 minutes,
arterial blood was taken for the measurement of glu-
cose, experimental insulin, 2-[14C]DG and hematocrit.
Plasma was stored at −20°C until analysis. Following
the insulin clamp, mice were killed via cervical dislocation
and tissues were immediately excised for analysis or stored
at −80°C. The heart, soleus, gastrocnemius, superficial
vastus lateralis and white adipose tissue from the epididy-
mal fat pad were collected.
Plasma analyses
Arterial insulin was assayed via a double antibody
method [47]. Plasma NEFAs (NEFA C kit; Wako
Chemicals, Richmond, VA, USA) and glucose were de-
termined spectrophotometrically as previously described
[18]. Plasma 2-[14C]DG was assessed as previously
outlined [45].
Tissue-specific substrate kinetics
Tissue 2-[14C]DG and tissue phosphorylated 2-[14C]DG
(2-[14C]DG-P) were determined as previously described
[45]. The metabolic index of glucose (Rg) uptake was cal-
culated [48] and expressed as previously described [49].
Mitochondrial respiration and enzymatic measurements
Cardiac peri-infarct fibers were prepared and saponin-
permeabilized as described [50]. High-resolution respi-
rometry (Oroboros Instruments, Innsbruck, Austria) was
performed in duplicate at 37°C in MiR05 (Final concen-
tration: 0.5 mM EGTA, 3 mM MgCl2⋅6H2O, 20 mM
taurine, 10 mM KH2PO4, 20 mM HEPES, 1 g/L BSA,
60 mM potassium-lactobionate, 110 mM sucrose, pH 7.1,
adjusted at 30°C). Substrates (final concentration) includedTable 1 Cardiovascular parameters in conscious, high-fat fed,
Baseline 7 d
SHAM MI + PBS MI +MSC SHAM
HR (bpm) 647 ± 16 662 ± 16 689 ± 9* 720 ± 8
FS (%) 49.58 ± 0.75 48.88 ± 1.02 48.74 ± 0.46 49.12 ± 0.78 29
EF (%) 82.07 ± 0.72 81.37 ± 1.01 81.23 ± 0.45 81.80 ± 0.76 56
IVSd (mm) 0.77 ± 0.02 0.81 ± 0.02 0.79 ± 0.01 0.76 ± 0.02 0
LVIDd (mm) 3.19 ± 0.07 3.21 ± 0.08 3.28 ± 0.04 3.02 ± 0.04 4
LVPWd (mm) 0.72 ± 0.01 0.69 ± 0.02 0.80 ± 0.02† 0.74 ± 0.02 0
IVSs (mm) 0.91 ± 0.02 0.91 ± 0.02 0.90 ± 0.01 0.88 ± 0.02 0
LVIDs (mm) 1.61 ± 0.04 1.65 ± 0.06 1.68 ± 0.03 1.54 ± 0.04 3
LVPWs (mm) 0.97 ± 0.02 0.98 ± 0.04 1.04 ± 0.01 0.88 ± 0.02 0
Data are mean ± SEM for n = 8-13 mice per group.
*p < 0.05 vs. SHAM at specified time point.
†p < 0.05 vs. MI + PBS at specified time point.
Abbreviations: HR, heart rate; FS, fractional shortening; EF, ejection fraction; IVSd, int
dimension; LVPWd, LV posterior wall thickness in diastole; IVSs, interventricular sept
wall thickness in systole.10 mM glutamate plus 2 mM malate and 5 mM pyru-
vate, 5 mM ADP and 10 mM succinate. 10 mM cyto-
chrome c was added to ensure the outer mitochondrial
membrane was intact after processing. Peri-infarct cit-
rate synthase activity was determined via previous
methods [18].Immunoblotting
Tissues were homogenized in a lysis buffer (final con-
centration) containing 20 mM NaCl, 20 mM Tris–HCl,
0.1 mM EDTA, 1% Triton X-100, 0.5% (wt./vol.) sodium
deoxycholate, and 0.1% β-Mercapto Ethanol (vol./vol.)
(pH 7.4) in the presence of a protease inhibitor cocktail
(Sigma-Aldrich, Oakville, ON, Canada) and phosphatase
inhibitor cocktail (Thermo Fisher Scientific, Mississauga,
ON, Canada). Cardiac (20–30 μg), gastrocnemius (40
μg) and white adipose tissue (40 μg) proteins were re-
solved on NuPAGE 4-12% (vol./vol.) Bis-Tris gels (Life
Technologies) and transferred to a polyvinylidene fluoride
membrane. Membranes were probed with peroxisome
proliferator-activated receptor gamma coactivator-1alpha
(PGC-1α; Santa Cruz Biotechnology, Santa Cruz, CA,
USA), glucose transporter 4 (GLUT4; Abcam, Cambridge,
MA, USA), hexokinase II (HKII; Chemicon, Temecula,
CA, USA), UCP3 (Abcam), phospho-Akt(Ser473) (p-Akt;
Cell Signaling Technology, Whitby, ON, Canada) and Akt
(Cell Signaling Technology) and oxidative phosphoryl-
ation complexes I-V (OXPHOS CI-CV; Abcam) anti-
bodies. A goat-anti-mouse secondary antibody (Thermo
Fischer Scientific) was used for the OXPHOS CI-CV
primary antibody cocktail. A goat-anti rabbit secondary
antibody (Cell Signaling Technologies) was used for all
other primary antibodies. Glyceraldehyde 3-phosphateC57BL/6 mice
ays post-MI 28 days post-MI
MI + PBS MI +MSC SHAM MI + PBS MI +MSC
699 ± 10 713 ± 12 710 ± 11 720 ± 13 731 ± 6
.88 ± 3.16* 30.90 ± 2.03* 48.99 ± 0.70 27.34 ± 2.84* 32.90 ± 2.02*
.51 ± 4.88* 58.48 ± 2.9* 81.48 ± 0.74 52.80 ± 2.93* 61.10 ± 2.88*†
.73 ± 0.04 0.84 ± 0.01*† 0.79 ± 0.01 0.76 ± 0.03 0.85 ± 0.01*†
.31 ± 0.24* 4.01 ± 0.13* 3.23 ± 0.08 4.32 ± 0.21* 4.27 ± 0.13*
.68 ± 0.07 0.86 ± 0.03*† 0.77 ± 0.02 0.71 ± 0.04 0.91 ± 0.03
.87 ± 0.05 0.92 ± 0.02 0.88 ± 0.01 0.84 ± 0.02 0.96 ± 0.01*†
.06 ± 0.28* 2.79 ± 0.16* 1.65 ± 0.06 3.17 ± 0.26* 2.89 ± 0.17*
.83 ± 0.09 1.01 ± 0.02*† 0.96 ± 0.02 0.82 ± 0.06* 1.11 ± 0.03*†
erventricular septal thickness in diastole; LVIDd, left ventricle (LV) end-diastolic


































































































































































* * * 
0 
SHAM MI+MSC MI+PBS 
Figure 2 Cardiac functional and hypertrophic indices. (a) Cardiac ejection fraction (%) prior to, seven and 28 days following a MI. n = 8-13
mice per group. (b) Cardiac fractional shortening (%) prior to, seven and 28 days following a MI. n = 8-13 mice per group. (c) Heart weight 36 days
post-MI surgery. n = 11-14 mice per group. (d) Heart weight-to-body weight ratio 36 days following a MI. n = 11-14 mice per group. (e) Time course
of body weight from one week prior to chronic left anterior descending coronary artery ligation to five weeks post-ligation. n = 10-12 mice per group.
(f) Tibial length 36 days following a MI. n = 11-14 mice per group. (g) Heart weight-to-tibial length 36 days post-MI. n = 11-14 mice per group. Data are
mean ± S.E.M. *p < 0.05 vs. SHAM. †p < 0.05 vs. MI + PBS.
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as a control for all immunoblots.
Statistical analyses
ANOVA or two-way repeated measures ANOVA were
performed to detect statistical differences (p < 0.05) as
appropriate followed by Tukey’s post hoc tests. All data
are reported as means ± SEM.Results
Stem cell therapy promotes improvement in cardiac
contractile function
Contractile abnormalities were observed using echocar-
diography (Table 1) in the MI + PBS group seven and
28 days following a MI as indicated by the depression in
ejection fraction (Figure 2a) and fractional shortening
(Figure 2b). The MSC-treated animals displayed a
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PBS group at seven days post-MI (Figure 2a). However,
the MSC-treated hearts exhibited a greater ejection
fraction than the MI + PBS mice at 28 days following
cardiac insult (Figure 2a). The MI +MSC mice, similar to
the MI + PBS animals, displayed a depression in fractional
shortening at seven and 28 days post-MI (Figure 2b).
Indices of cardiac structural alterations were also
assessed. Heart weight (Figure 2c) and heart-to-body
weight (Figure 2d) were increased in MI + PBS mice 36 days
post-MI. A comparable elevation in these hypertrophy
markers was observed in the MSC-treated mice (Figure 2c,
d). Of note, measurement of body weight from one week
prior to the ligation surgery to five weeks post-MI indicated
that the MI + PBS mice were lower as a result of the MI
































































































Figure 3 Regional insulin-stimulated cardiac glucose uptake. (a) Meta
peri-infarct region of the left ventricle. Cardiac Rg values are relative to brai
infarct peroxisome proliferator-activated receptor gamma coactivator-1alph
determined by immunoblotting. (e) Left ventricle and (f) peri-infarct phosp
determined by immunoblotting. (g) Representative immunoblotting perfor
are normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) co
are mean ± S.E.M. *p < 0.05 vs. SHAM. †p < 0.05 vs. MI + PBS.displayed a comparable body weight to animals of the
SHAM group (Figure 2e). Given the changes in body
weight, tibial length was used to normalize heart weight
and provide another index of pathological cardiac hyper-
trophy. Tibial length was unchanged between groups
(Figure 2f ). Both infarcted groups displayed an elevated
heart weight-to-tibial length compared to the SHAM
group (Figure 2f) indicating a hypertrophic response to
the infarct that was not inhibited by the MSC therapy.
Enhanced insulin-stimulated cardiac glucose utilization in
MSC-treated mice
Isotopic glucose (2-[14C]DG) was administered during
the insulin clamps to assess tissue-specific glucose up-
take. A MI did not influence regional insulin-stimulated

































bolic index of glucose uptake (Rg) in the remote left ventricle and (b)
n Rg. n = 8-9 mice per group. (c) Remote left ventricle and (d) peri-
a (PGC-1α), glucose transporter 4 (GLUT4) and hexokinase II (HKII) as
ho-Akt (p-Akt), Akt and p-Akt-to-total Akt ratio (p-Akt/Akt) as
med to measure PGC-1α, GLUT4, HKII, p-Akt and Akt. Cardiac proteins
ntent and are relative to the SHAM group. n = 6 mice per group. Data
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http://www.cardiab.com/content/12/1/128ventricle (MI + PBS LV) and the peri-infarct region (MI +
PBS PI) in the MI + PBS animals were comparable to the
SHAM group (Figure 3a,b). In contrast, intramyocardial in-
jection of MSCs enhanced cardiac Rg in response to insulin.
The remote left ventricle of the MSC-treated mice (MI +
MSC LV) displayed greater Rg compared to that of the
MI+PBS mice (Figure 3a). Furthermore, the insulin-mediated
response of the peri-infarct region of the MI +MSC hearts
(MI +MSC PI) was more apparent. The MI +MSC PI re-
gion exhibited a higher Rg than the SHAM hearts and the
peri-infarct region of the MI + PBS group (Figure 3b).
To identify the mechanisms by which MSC adminis-
tration promoted cardiac glucose uptake key regulators
of glucose metabolism were evaluated. The remote left


































































































Figure 4 Cardiac mitochondrial function and characteristics. (a) Peri-in
by glutamate, malate and pyruvate (V0), maximal oxygen consumption (AD
complex I (VMAX-CI) and maximal convergent oxygen flux supported by glu
group. (b) Respiratory control ratio (RCR; defined as VMAX-CI/V0). n = 8-9 mic
mg protein). n = 8-9 mice per group. (d) Remote Left ventricle and (e) peri
I-V (CI-CV) and uncoupling protein 3 (UCP3) as determined by immunoblot
OXPHOS complexes I-V and UCP3. Cardiac protein was normalized to glyce
expressed relative to the SHAM group. n = 6 mice per group. Data are meawere comparable between groups (Figure 3c,d). The in-
sulin signalling pathway was also probed by determining
p-Akt(Ser473) and total Akt. Again, the regional p-Akt-
to-Akt ratio was similar between groups (Figure 3e,f ).
MSC transplantation augments mitochondrial physiology
Given both contractile function and substrate utilization
are influenced by energy metabolism, polarographic oxy-
gen flux measurements were performed to assess integra-
tive mitochondrial OXPHOS. The MI + PBS peri-infarct
fibers exhibited a reduced basal oxygen consumption (V0)
supported by glutamate, malate and pyruvate compared to
the SHAM group (Figure 4a). Interestingly, MSC-treated
hearts displayed an even further depression in basal oxy-



















































farct permeabilized cardiac fiber basal oxygen consumption supported
P-stimulated) supported by glutamate, malate and pyruvate through
tamate, malate, pyruvate and succinate (VMAX-CI+CII). n = 8-9 mice per
e per group. (c) Peri-infarct citrate synthase activity (CSA) (mmol/min/
-infarct mitochondrial oxidative phosphorylation (OXPHOS) complexes
ting. (f) Representative immunoblotting of the regional protein levels
raldehyde-3-phosphate dehydrogenase (GAPDH) content and
n ± S.E.M. *p < 0.05 vs. SHAM. †p < 0.05 vs. MI + PBS.
Table 2 Biometric characteristics of high-fat fed,
C57BL/6 mice
SHAM MI + PBS MI +MSC
Fasting Plasma
Glucose (mM)
11.37 ± 0.48 10.81 ± 0.43 9.06 ± 0.32*†
Fasting Plasma
NEFA (mM)
1.04 ± 0.05 1.09 ± 0.06 0.8 ± 0.06*†
Fasting Plasma
Insulin (μU/ml)
60.08 ± 13.22 50.76 ± 16.15 42.46 ± 11.13
Experimental Plasma
Insulin (μU/ml)
128.02 ± 15.77 108.17 ± 8.84 160.04 ± 24.32
Muscle (%) 68.70 ± 1.76 77.75 ± 1.96* 67.88 ± 2.38†
Fat (%) 29.53 ± 1.80 20.74 ± 2.02* 30.25 ± 2.42†
Free Fluid (%) 1.77 ± 0.11 1.51 ± 0.17 1.87 ± 0.27
Data are mean ± SEM.
n = 11-12 mice per group for plasma glucose, n = 10-12 for plasma NEFA, n =
8-9 for fasting plasma insulin, n = 8 for experimental plasma insulin, n = 9-13
for body composition.
*p < 0.05 vs. SHAM.
†p < 0.05 vs. MI + PBS.
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consumption through complex I was reduced in MI + PBS
and MI +MSC animals (VMAX-CI; Figure 4a). Similarly,
ADP-stimulated oxygen flux via convergent electron flux
through mitochondrial complexes I + II was reduced in
both infarcted groups (VMAX-CI + CII; Figure 4a). Intri-
guingly, the respiratory control ratio (RCR) was reduced
in the MI + PBS hearts compared with the MI +MSC car-
diac fibers (Figure 4b). This suggests a decrease in
OXPHOS efficiency in the MI + PBS mice. Citrate syn-
thase activity was assessed to identify differences in mito-
chondrial content. The MI + PBS group exhibited a decline
in citrate synthase activity (Figure 4c). The preservation of
cardiac citrate synthase activity in the MI +MSC mice
prompted the evaluation of mitochondrial proteins in an
effort to identify mechanisms contributing to the reduced
V0 but greater RCR. Protein expression of mitochondrial
OXPHOS complexes showed the MI +MSC mice to have
a lower complex I protein in the remote left ventricle re-
gion (Figure 4d,f). Similarly, the MI + PBS and MI +MSC
peri-infarct region exhibit a reduced complex I protein
compared to the SHAM heart (Figure 4e,f). Surprisingly,
there was an added effect of the MSC therapy. The MI +
MSC peri-infarct region displayed a lower complex II and
complex V compared to the SHAM hearts (Figure 4e,f).
Another potential contributor to the lower basal oxygen
flux but elevated RCR is the peri-infarct UCP3 that was
lower in the MI +MSC mice (Figure 4e,f).
Reduced fasting plasma glucose and fatty acids following
MSC administration
High-fat diets have been reported to promote an increase
in tissue UCP3 protein. More specifically, cardiac UCP3
positively correlates with circulating fatty acid levels [37].
As such, we evaluated fasting plasma non-esterified fatty
acid (NEFA) concentration. There was a lowering of NEFA
levels in the MI +MSC mice (Table 2). In addition, fasting
plasma glucose concentration was reduced following MSC
therapy (Table 2). Of note, arterial insulin concentrations
in the fasted state and during the insulin clamp were both
similar between groups (Table 2).
Systemic insulin sensitivity elevated by MSC injection
The lowering of fasting plasma glucose and fatty acids
suggested a systemic effect of the MSC administration.
To this end, insulin clamps were performed in the con-
scious, unrestrained mouse to evaluate whole body glucose
disposal in response to insulin in vivo. The GIR required to
maintain an arterial glucose concentration of 7.0 mM was
elevated in MI +MSC mice throughout the duration of the
insulin clamp (Figure 5a). The GIR for the MI + PBS mice
was similar to the SHAM group (Figure 5a). Arterial glu-
cose was comparable between groups during the insulin
clamp (Figure 5b).Increased peripheral tissue glucose uptake post-MSC
therapy
In agreement with the increased GIR, the MSC admin-
istration increased insulin-stimulated Rg in peripheral
tissues. The MI +MSC soleus, superficial vastus lateralis,
gastrocnemius and white adipose tissue had a greater Rg
compared to the same tissues of the SHAM group
(Figure 6a-d). The MI +MSC gastrocnemius also exhibited
an elevated Rg compared to that of the MI + PBS mice
(Figure 6c). The MI + PBS mice displayed a higher Rg
in white adipose tissue compared to the SHAM group
(Figure 6d). The protein expression of regulators in-
volved in insulin-mediated Rg was evaluated in the
gastrocnemius and white adipose tissue. GLUT4 was
higher in the MI +MSC gastrocnemius compared to
the SHAM group (Figure 6e,f). Also, gastrocnemius p-Akt
and the p-Akt-to-Akt ratio were greater in the MI +MSC
mice (Figure 6e,f). Both the MI +MSC and MI + PBS
groups displayed higher GLUT4 in the white adipose tis-
sue (Figure 6g,h). However, only the MI +MSC exhibited
elevated p-Akt relative to the SHAM group in white adi-
pose tissue (Figure 6g,h). Furthermore, the p-Akt-to-Akt
ratio in MI +MSC white adipose tissue was greater than
that of the SHAM and MI + PBS mice (Figure 6g).
Discussion
Numerous studies have reported that cell-based thera-
peutics can minimize insult to the infarcted heart, in
large part, through trophic mechanisms [10,13]. How-
ever, as stem cell therapy transfers to clinical trials and
ideally to routine use in the clinical setting a clearer un-
derstanding as to how the transplanted cells improve
outcomes is needed. To gain greater insight into the





















































SHAM MI+MSC MI+PBS 
Figure 5 Whole body insulin sensitivity and blood glucose during the hyperinsulinemic-euglycemic (insulin) clamp. (a) Glucose infusion
rate (GIR) during the insulin clamp. The GIR is equivalent to the whole body glucose disposal rate in response to venous insulin infusion. The
insulin infusion was for approximately 120 minutes prior to 2-[14C]deoxyglucose (2-[14C]DG) administration. The GIR is displayed as a time course
commencing twenty minutes prior to administration of 2-[14C]DG (−20 minute time point) to 30 minutes following 2-[14C]DG infusion (30 minute
time point). (b) Arterial, blood glucose concentration following 2-[14C]DG for 30 minutes post-administration. Data are mean ± SEM for n = 9-12
mice per group. *p < 0.05 vs. SHAM.
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http://www.cardiab.com/content/12/1/128of physiological relevance is required. Few studies have in-
cluded type 2 diabetes and/or its associated metabolic
dysregulation on the effect of stem cell transplantation in
the infarcted heart. Yan et al. [51] assessed the influence of
induced-pluripotent stem (iPS) cell administration in the
db/db mouse heart following a MI. Echocardiography re-
vealed that 14 days post-MI left ventricle contractile dys-
function was minimized by iPS cell transplantation [51].
The current study expands on the work of Yan and col-
leagues [51] by employing a diet-induced insulin resistant
C57BL/6 mouse model and assessing the ability of MSC
administration to minimize cardiac systolic abnormalities
post-infarct. We report the MSC therapy to improve car-
diac ejection fraction 28 days post-MI. This indicates that
MSC transplantation holds similar potential in restoring
left ventricle systolic function in the presence of diet-
induced systemic metabolic insults. Furthermore, our ex-
periments investigate beyond cardiac contractile function
to evaluate the effect of MSC transplantation on metabolic
characteristics that may minimize dysfunction.
The superior contractile function in the MSC-treated
mice may be due to the ability of the hearts to more ef-
fectively utilize substrates and synthesize ATP. The
current study demonstrates intramyocardial administra-
tion of MSCs to improve the ability of the heart to
utilize glucose in the remote left ventricle and peri-
infarct region. This improvement in glucose uptake
could assist in energy provision. To provide insight into
the means through which the MSC transplantation ele-
vated cardiac glucose uptake molecular regulators of
glucose metabolism were evaluated. The current study
did not expose alterations in regional cardiac levels of
PGC-1α, GLUT4, HKII, p-Akt, Akt and the p-Akt-to-
Akt ratio. This suggests key proteins involved in glucoseuptake and insulin signalling were not augmented by the
MSC treatment in the heart. The absence of changes in
these proteins led us to explore mitochondrial function
as a possible mechanism by which glucose would be uti-
lized at a higher rate.
Downstream of glucose transport and glycolysis, mito-
chondria OXPHOS acts as a link between glucose up-
take and ATP generation. Early studies evaluating the
effect of MSC transplantation show an improvement in
the peri-infarct and whole left ventricle phosphocreatine
(PCr)-to-ATP ratio [14-16]. The PCr-to-ATP ratio reflects
efficiency of myocardial energy provision, and correlates
well with left ventricle contractile function [14,52-54].
Furthermore, MSC therapy reduces basal mitochondrial
oxygen consumption (V0) and improves cardiac RCR
(VMAX-CI/V0) [18]. V0 represents futile respiration that
does not contribute to ATP synthesis and a lower basal
oxygen flux helps increase RCR; which is indicative of a
more efficient OXPHOS. Mitochondrial dysfunction has
been theorized to promote insulin resistance [55]. Con-
versely, improved mitochondrial function may help allevi-
ate impaired glucose uptake and assist in greater ATP
synthesis. In the current study, MSC therapy was also able
to lower V0 and increase RCR. The ability of MSCs to pro-
mote these alterations on mitochondrial function may be
due to a direct influence on OXPHOS complexes. Jameel
et al. [56] indicate that MSC administration for the in-
farcted heart reduces gene expression of complex I sub-
units. We report that in the peri-infarct region, there was
a decline in complex I protein levels following a MI. How-
ever, MSC transplantation enhanced the reduction in
complex I as indicated by the decline induced in the re-
mote left ventricle and peri-infarct region. Complex II and














































































































































White adipose tissue 
SHAM MI+MSC MI+PBS 
Figure 6 Insulin-stimulated peripheral tissue glucose utilization. (a) Metabolic index of glucose uptake (Rg) in the soleus. (b) Metabolic index
of glucose uptake (Rg) in the superficial vastus lateralis. (c) Metabolic index of glucose uptake (Rg) in the gastrocnemius. (d) Metabolic index of
glucose uptake (Rg) in white adipose tissue. Tissue Rg values are relative to brain Rg. n = 9 mice per group. (e) Gastrocnemius glucose transporter
4 (GLUT4), phospho-Akt (p-Akt), Akt and p-Akt-to-total Akt ratio (p-Akt/Akt) as determined by immunoblotting. n = 6-8 mice per group. (f)
Representative immunoblotting performed to measure gastrocnemius GLUT4, p-Akt and Akt. (g) White adipose tissue glucose transporter 4
(GLUT4), phospho-Akt (p-Akt), Akt and p-Akt-to-total Akt ratio (p-Akt/Akt) as determined by immunoblotting. n = 6 mice per group. (h)
Representative immunoblotting performed to measure white adipose tissue GLUT4, p-Akt and Akt. Protein levels are normalized to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) content and are expressed relative to the SHAM group. Data are mean ± S.E.M. *p < 0.05 vs.
SHAM. †p < 0.05 vs. MI + PBS.
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http://www.cardiab.com/content/12/1/128A reduction in OXPHOS complexes I, II and V may ex-
plain the diminished V0 as a repressed complex number
would subdue electron flux and oxygen consumption. An-
other potential reason for the lower V0 and elevated RCR
is alterations in UCP3. UCP3 has been suggested to func-
tion as a potential OXPHOS uncoupler [57]. As such, areduction in protein may promote a decline in UCP3-
mediated uncoupling.
Increases in tissue UCP3 are often more pronounced
with high-fat diets and with elevated circulating fatty acids
[37,58]. We report that MSC-treated mice exhibited a re-
duction in fasted plasma NEFAs. This decline would
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http://www.cardiab.com/content/12/1/128promote a lower tissue expression of UCP3. Further sys-
temic influence of the MSC therapy was observed in fasting
plasma glucose. We found plasma glucose levels were di-
minished in the MSC-treated animals. In agreement, animal
studies indicate that MSC therapy is capable of lowering
blood glucose levels in both type 1 diabetes [59,60] and type
2 diabetes [61]. A recent pilot clinical study has reported a
reduction in blood glucose in individuals with type 2 dia-
betes following MSC transplantation [62].
The exact means by which MSC exert these effects on
metabolism have yet to be elucidated. To date, the ma-
jority of studies evaluating stem cell transplantation in
diabetes have focused on the ability of the administered
cells to regenerate and/or protect the insulin-producing
beta cells of the pancreas as a means of providing im-
proved glucose control and reducing diabetic complica-
tions [63]. To the authors’ knowledge, only a single
study has evaluated the influence of cell-based therapy
on peripheral tissue glucose disposal as a mechanism
through which the treatment reduces hyperglycemia. Si
et al. [61] employed insulin clamps to test whether intra-
venous MSC administration improves whole-body insu-
lin sensitivity in streptozotocin/high-fat diet-induced
diabetes rodents. It was reported that MSC therapy in-
creased GIR but there was not a complete restoration to
that of a chow fed animal [61]. We achieved comparable
results employing insulin clamps to show the MSC-
treated animals display greater systemic insulin sensitiv-
ity. Mice receiving MSC displayed an approximately 40%
increase in the GIR compared to SHAM mice. Although
the MSCs were administered via an intramyocardial in-
jection, previous reports have identified MSC to persist,
albeit low in magnitude, in peripheral tissues such as the
lungs, spleen and liver [64,65]. As such, a systemic effect
was not completely unanticipated. Moreover, the current
study provides further support for a system-wide eleva-
tion in insulin-mediated glucose uptake by combining
the insulin clamp with isotopic techniques to evaluate
tissue-specific glucose utilization. In addition to increased
cardiac glucose uptake, the soleus, superficial vastus
lateralis, gastrocnemius and white adipose tissue exhibited
an elevated rate of insulin-stimulated glucose uptake
following MSC transplantation. The rise in glucose
utilization in a range of insulin-sensitive tissues sug-
gests the stem cell therapy is indeed acting in a sys-
temic fashion rather than solely via tissue-specific
mechanisms.
To address the mode by which the MSC treatment
promoted glucose uptake in the selected tissues, GLUT4
protein was examined. Both gastrocnemius and white
adipose tissue total GLUT4 protein was elevated in the
MSC-treated mice. In the current study plasma fasting
and experimental insulin concentrations were compar-
able between groups, however, there was an insulin-dependent influence conferred by the MSC transplant-
ation. The gastrocnemius and white adipose tissue
displayed higher p-Akt and an elevated p-Akt-to-Akt ra-
tio. This suggests the cell therapy also augments the
PI3K-Akt pathway to enhance glucose uptake.
The comprehensive in vivo approach employed for
evaluating insulin sensitivity, substrate uptake and cardiac
function following diet-induced insulin resistance and a
standardized MI in the conscious mouse provides a greater
understanding of the influence of MSC therapy on the dia-
betic infarcted heart. Despite this, a few readily apparent
limitations exist. First, it is not clear if the improved ejec-
tion fraction is the result of direct cardio-protection or sys-
temic alterations. The improved insulin sensitivity may
give the heart added metabolic flexibility to meet its en-
ergetic requirements. Similarly, the reduction in plasma
NEFAs may lessen OXPHOS uncoupling for more efficient
ATP synthesis. In experimental models, ad libitum feeding
of mice a high-fat diet with 55–60% of the caloric content
being derived from fatty acids induces cardiovascular ir-
regularities. After 16 weeks of HFF, systolic and diastolic
blood pressure is markedly elevated compared to chow fed
mice (11% calories by fat) [66]. Park et al. [67] identified
C57BL/6 mice to exhibit impaired systolic performance
following 20 weeks of HFF as indicated by fractional short-
ening. The animals evaluated in the current study were
HFF for 13 weeks. As such, the therapeutic importance of
peripheral glucose uptake and reduced hyperglycemia may
increase as the dietary intervention is prolonged.
Another potential limitation of the present study is
that the animals were not weight-matched at the time of
glucose uptake evaluation. In the infarct-only animals,
body weight was significantly lower following the MI
event. This was associated with a reduced accumulation
of body fat. Many of the metabolic aberrations associated
with the HFF model are connected to the induction of
obesity (fat deposition) [68]. Thus, the increase in the
metabolic index of glucose uptake in the adipose tissue of
the MI + PBS group is believed to be the result of the MI
insult limiting comparable weight gain in these mice.
Finally, given the metabolic parameters were performed
in the peri-infarct region of the heart, differential cell via-
bility may be of modest concern. In the clinical setting, tis-
sue salvage and infarct size reduction is based on the
assumption that the core of the infarct is severely ischemic
and necrotic [69]. Moreover, this core is surrounded by an
area of jeopardized tissue called the peri-infarct region
that may be salvaged by reperfusion efforts [69]. In experi-
mental ligation models this is not observed. Rather than a
progressive transition from infarct to viable tissue there is
an abrupt, but irregular, changeover from ischemic zone
to perfused, viable tissue [69,70]. While this is a limitation
in matching the clinical setting exactly, it is also an advan-
tage to the studies conducted because it largely minimizes
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following the MI event.
Conclusions
In summary, the novel findings of this study are the
MSC-mediated increase in both cardiac glucose uptake
and mitochondrial OXPHOS efficiency. These metabolic
improvements may assist in greater ATP provision for
contractile demands following a MI. Our results also
demonstrate MSC transplantation to reduce hypergly-
cemia, hyperlipidemia and improve peripheral tissue
insulin-mediated glucose uptake. These findings differ
from the effects of MSC therapy in the absence of type 2
diabetes and/or its metabolic abnormalities. Previous
work by the authors evaluating the therapeutic influence
of MSC transplantation on cardiac glucose utilization
post-MI in chow fed mice did not identify MSC-induced
alterations in cardiac glucose metabolism [18]. Further-
more, no apparent whole body effect on insulin sensitiv-
ity was mediated by MSC transplantation [18]. By
utilizing a combined diet-induced insulin resistant/MI
model the current study identifies that not only does
MSC transplantation potentially lessen impairment in
cardiac contractile performance via augmentation of
cardiac-specific metabolism but also holds the ability to
reach farther than the heart to dampen systemic
dysregulation that may contribute to the maladaptive al-
terations in cardiac function.
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